Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma or Serum? A Pilot Evaluation of Matrix Selection for Integrated Metabolomics and Exposomics of Clinical Samples.

Toxics·2026
Same author

Expanding vaginal microbiome pangenomes via a custom MIDAS database reveals <i>Lactobacillus crispatus</i> accessory genes associated with cervical dysplasia.

mSystems·2026
Same author

Unplanned Excision and the Race to Cure Sarcomas: Commentary on an article by Jacob Jahn, BS, et al.: "Effect of Timing of First Consultation with a Sarcoma Specialist Following Unplanned Excision. Oncologic Outcomes of Patients with Soft-Tissue Sarcomas".

The Journal of bone and joint surgery. American volume·2026
Same author

The Phylum Fusobacteriota Is Associated with Colorectal Cancer-Specific Mortality: Results from the Translational Research Program in Cancer Differences across Populations.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Tabular foundation model predicts alternative lengthening of telomeres (ALT) and identifies SMARCAL1 as a target in ALT-driven cancers.

bioRxiv : the preprint server for biology·2026
Same author

FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy.

Cancer research·2026

Related Experiment Video

Updated: Jun 3, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by

Courtney R Schott1,2, Amanda L Koehne1, Leanne C Sayles1

  • 1Department of Pediatrics, University of California San Francisco, San Francisco, California.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 13, 2023
PubMed
Summary

New osteosarcoma cell models accurately reflect patient metastatic disease, aiding research into rare cancers. These models show promise for testing new therapies against osteosarcoma metastasis.

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

9.4K
Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study
02:35

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Published on: March 22, 2024

847

Related Experiment Videos

Last Updated: Jun 3, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

9.4K
Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study
02:35

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Published on: March 22, 2024

847

Area of Science:

  • Oncology
  • Genomics
  • Translational Research

Background:

  • Osteosarcoma is a rare cancer with poor outcomes for metastatic disease.
  • Its complex and heterogeneous genomic landscape necessitates diverse preclinical models.
  • Understanding osteosarcoma metastasis is crucial for developing effective treatments.

Purpose of the Study:

  • To develop and characterize novel osteosarcoma patient-derived xenograft (PDX)-derived cell lines.
  • To evaluate these models for their ability to recapitulate the metastatic spectrum of osteosarcoma.
  • To assess the preclinical efficacy of a targeted therapy in these models.

Main Methods:

  • Whole-genome and RNA sequencing of patient samples, PDXs, and PDX-derived cell lines.
  • In vivo characterization of metastatic phenotype in intravenous and orthotopic murine models.
  • Preclinical testing of a cyclin-dependent kinase inhibitor (dinaciclib) in an orthotopic amputation model.

Main Results:

  • PDX-derived cell lines largely maintained patient expression profiles, with some developing whole-genome duplication.
  • Cell lines exhibited heterogeneous metastatic capacity and tissue tropism in vivo.
  • The cyclin-dependent kinase inhibitor dinaciclib significantly reduced metastatic tumor burden.

Conclusions:

  • Osteosarcoma PDX-derived cell lines effectively model the variation in metastasis predilection sites seen in patients.
  • This panel of new cell lines offers a valuable resource for the osteosarcoma research community.
  • These models will advance the study of osteosarcoma biology and preclinical therapeutic development.